Avadel Pharmaceuticals PLC expected to post a loss of 4 cents a share - Earnings Preview

Avadel Pharmaceuticals

28/02/2025 14:04

Avadel Pharmaceuticals PLC AVDL.OQ AVDL.O is expected to show a rise in quarterly revenue when it reports  results on March 3 for the period ending December 31 2024

The Dublin-based  company is expected to report a 157.2% increase in revenue to $50.033 million from $19.45 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Avadel Pharmaceuticals PLC is for a loss of 4 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Avadel Pharmaceuticals PLC is $18.00​, above​ its last closing price of $7.68. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.06
-0.06
-0.03
Beat
45.7
Jun. 30 2024
-0.17
-0.16
-0.14
Beat
10
Mar. 31 2024
-0.20
-0.21
-0.30
Missed
-44.4​
Dec. 31 2023
-0.23
-0.26
-0.29
Missed
-11.8
​​Sep. 30 2023
-0.38
-0.37
-0.41
Missed
-10.1
Jun. 30 2023
-0.38
-0.38
-0.83
Missed
-116​
Mar. 31 2023
-0.34
-0.38
-0.48
Missed
-27.4
Dec. 31 2022
-0.30
-0.27
-0.46
Missed
-69.7

This summary was machine generated February 28 at 14:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)